Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted DNA-seq of Human HepG2 cells following editing with CRISPR/Cas9 upon chromatin modulation with TSA and EZH2i

ABSTRACT: We sought to characterise how chromatin states affected CRISPR/Cas9 activity and the induced indel profiles. We used two different doses of Trichostatin and two different doses of a EZH2 inhibitor to modulate the chromatin state and then performed targeted DNA-seq of selected sgRNA target regions to identify the indels.

INSTRUMENT(S): Illumina MiSeq

ORGANISM(S): Homo sapiens

SUBMITTER: Paola Scaffidi

PROVIDER: E-MTAB-7091 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Targeted DNA-seq of Human HepG2 cells following editing with CRISPR/Cas9

Project description:We performed a large-scale genome-wide characterisation of indels generated following editing with CRISPR/Cas9. We used pools of sgRNAs and performed targeted capture and sequencing of the edited regions in HepG2 cells.

2018-12-13 | E-MTAB-7095 | biostudies-arrayexpress

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

Project description:CRISPR screen data

2023-05-31 | E-MTAB-12929 | biostudies-arrayexpress

RNA-seq data of rs2280381-containing region knock out clone in U-937 cell line

Project description:rs2280381 is an autoimmune disease susceptible variant, which has been reported to be associated with SLE, RA and SSc. Genetic and epigenomic analysis indicate that the rs2280381-containing region is an enhancer region in monocyte. To test the function and regulated genes of the rs228381-containing region, we deleted the rs2280381 ~120bp sequence in U-937 cells, and performed the RNA-seq to detect the gene expression profiles.

2022-02-25 | E-MTAB-11306 | biostudies-arrayexpress

RNA seq in U-937 cells wildtype clones and rs2431697 region deletion clones

Project description:rs2431697 is a SLE risk SNP, genetic and epigenomic analysis indicate that rs2431697-containing region is an enhancer region. To test the function and regulated genes of rs2431697-containing genes, we deleted rs2431697-containing region in U-937 cells, and performed the RNA-seq to detect the gene expression profiles.

2020-11-05 | E-MTAB-8978 | biostudies-arrayexpress

RNA-seq of rs2280381-containing region knock out clone in U937

Project description:rs2280381 is an autoimmune disease susceptible loci, which have be reported to be associated with SLE, RA and SSc.Genetic and epigenomic analysis indicate that rs2280381-containing region is an enhancer region in monocyte. To test the function and regulated genes of rs228381-containing region, we deleted rs2280381 ~120bp sequence in U-937 cells, and performed the RNA-seq to detect the gene expression profiles.

2021-07-01 | E-MTAB-10126 | biostudies-arrayexpress

Targeting EZH2 methyltransferase activity in ARID1A mutated cells as a synthetic lethal therapeutic strategy

Project description:ARID1A, an epigentic modifier, is often mutated in ovarian clear cell carcinoma (OCCC). In addition, EZH2 is frequently upregulated in OCCC. Inhibtion of EZH2 with an inhibitor (GSK126) selectively inhibits ARID1A-mutated cells. This study was designed to understand changes in gene expression profiles following EZH2 inhibition or ARID1A restoration. Chromatin remodelers such as ARID1A are frequently mutated in a broad array of cancers. However, targeted cancer therapy based on ARID1A mutation status has not been described. Intriguingly, ARID1A mutated cancers typically lack genomic instability, suggesting significant involvement of epigenetic mechanisms. Here we show that inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A mutated cells. Remarkably, ARID1A mutation status correlated with response to EZH2 inhibitor. Genome-wide profiling revealed antagonistic roles of ARID1A and EZH2 in gene regulation. Further, we identified PIK3IP1 as a direct ARID1A/EZH2 target gene whose upregulation contributes to the observed synthetic lethality in the EZH2 inhibitor treated ARID1A mutated cells. Significantly, EZH2 inhibitor caused the regression of established ARID1A mutated tumors in vivo. Together, this data demonstrate a synthetic lethality between ARID1A mutation and EZH2 inhibition. They indicate that pharmacological inhibition of EZH2 represents a novel treatment strategy for ARID1A mutated cancers.

2015-01-20 | E-GEOD-54979 | biostudies-arrayexpress

Analysis of Cas9/sgRNA mutagenic activity at a variety of loci in zebrafish (Run6)

Project description:Analysis of Cas9/sgRNA mutagenic activity at a variety of loci in zebrafish. Each loci has a control, where no Cas9/sgRNA were injected. This is amplicon sequencing with Illumina, after PCR amplification. Data was processed with ampliCan R package version 1.1.1.

2017-12-25 | E-MTAB-6310 | biostudies-arrayexpress

Analysis of Cas9/sgRNA mutagenic activity at a variety of loci in zebrafish (Run 9)

2017-12-15 | E-MTAB-6357 | biostudies-arrayexpress

Analysis of Cas9/sgRNA mutagenic activity at a variety of loci in zebrafish (Run 10)

2017-12-15 | E-MTAB-6358 | biostudies-arrayexpress

Analysis of Cas9/sgRNA mutagenic activity at a variety of loci in zebrafish (Run 8)

2017-12-15 | E-MTAB-6356 | biostudies-arrayexpress